AKANDA CORP.

AKAN
About the company

Akanda Corp., through its subsidiaries, operates as early-stage cannabis company in Mexico. It is involved in medical cannabis cultivation, manufacturing, and sale; and leasing and/or rental of fiber optic networks and telecommunication towers. The company is based in Toronto, Canada.

Country: United KingdomPrice: $1.36Market Cap: $3.6M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

2 / 12

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedNEUTRALFAILPASSFAILFAILFAILFAILPASSFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 8✗ 20▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.7x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-4220.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-4220.5%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.7x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-217.4%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-169.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.7x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low217% of trailing low ($0.63)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-114.11%; #5454/6340 (top 86.0%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+1.1913; #1207/6449 (top 18.7%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.65x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.2331; #3626/5247 (top 69.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-169.33%; #4178/4519 (top 92.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+117.25%; #276/6202 (top 4.5%)
      ✓OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-4.9M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-6.1M
      ✗LynchPositive and growing
      Operating Cash Flow$-4.0M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-50.29%, ROA=-51.76%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-169.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/4 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-218.3%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/4 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-6.1M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-169.33%; #4178/4519 (top 92.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue Growth
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.11 (2019) -> $-3.93 (2024)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth97.5%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency2/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 124.8% -> 24.9%, operating margin -770.2% -> -523.8%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Profitability6% pass✓ 6✗ 29▾

      15 of 16 flag AKAN's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/7 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/7 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-69.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-523.8% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-4.9M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-95.8%
      ✗Lynch> 15%
      EBIT / Enterprise Value-4220.5%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-4220.5%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-51.76%
      ✗PiotroskiROA > 0
      ROA Change YoY-365.10% -> -51.76% (delta: +313.35%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-50.29%, ROA=-51.76%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY14.0% -> 24.9%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-95.8%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.7x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-69.6% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-523.8%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-95.8%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-770.2% (2022) -> -523.8% (2024)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 124.8% -> 24.9%, operating margin -770.2% -> -523.8%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-114.11%; #5454/6340 (top 86.0%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+2.63%; #3232/3702 (top 87.3%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-95.78%; #4578/5226 (top 87.6%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-1.2457; #5337/5884 (top 90.7%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/6 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Efficiency13% pass✓ 2✗ 9▾

      7 of 8 flag AKAN's efficiency — Graham, Buffett, Greenblatt +4 more

      Current Ratio1.39
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-239.9%
      ✗Buffett> 10%
      ROIC - WACC-249.9%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.18 -> 1.39
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.05x -> 0.11x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities1.39
      ✗Dreman> 1.5
      Return on Invested Capital-74.8%
      ✗Munger> 15%
      ROIC (high and growing)FY2022: ROIC=-52.3%; FY2023: ROIC=-8363.1%; FY2024: ROIC=-74.8%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/4 years above 12% (latest -74.8%)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts14% pass✓ 2✗ 12▾

      Split decision: 12 FAIL · 2 NEUTRAL · 2 PASS

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)•GreenblattNot ranked•PiotroskiNEUTRAL (F-Score 7)✗DremanFAIL (2/11)✓MungerPASS (2/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✓TempletonPASS (4/8)✗SleepFAIL (0/6)✗AsnessFAIL (Rank #2283/2370 (Top 96.3%))✗NeffFAIL (1/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage50% pass✓ 9✗ 6▾

      6 of 12 pass — Graham, Buffett, Lynch +3 more object

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.08, IC: -43.8x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.08
      ✓Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change28.25% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.39
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.08
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.08
      ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-43.8x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.08
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.0825; #1195/4210 (top 28.4%)
      ✓AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($3.6M)
    Revenue: $836664.00+97.5% YoY
    Net Income: $4.1M+87.3% YoY

    Financial Snapshot

    Operating Margin-523.8%
    Return on Equity-95.8%
    Debt / Equity0.08
    Current Ratio1.39
    EPS (Diluted)$-3.93

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    MetricFY 2024
    Sources
    • 20-F · 2025-04-30
    FY 2023
    Sources
    • 20-F · 2024-05-01
    FY 2022
    Sources
    • 20-F · 2023-05-02
    FY 2021
    Sources
    • 20-F · 2022-05-02
    FY 2020
    Sources
    • 20-F · 2022-05-02
    Market Cap$3.6Mcurrent$2.7Best.$136.4Best.$1.6Test.--
    Revenue$836.7K↑97%$423.7K↓84%$2.6M↑6223%$41.4K↑1909%$2.1K
    Operating Income-$4.4M↓20%-$3.7M↑82%-$20.2M↓685%-$2.6M↓54%-$1.7M
    Net Income-$4.1M↑87%-$32.3M↓177%-$11.7M↓43%-$8.1M↓253%-$2.3M
    EPS (Diluted)$-3.93↑45%$-7.16↓1736%$-0.39↑22%$-0.50↓178%$-0.18
    Gross Margin24.9%↑78%14.0%↓89%124.8%↑3350%-3.8%↑100%-2821.3%
    Operating Margin-523.8%↑39%-863.6%↓12%-770.2%↑88%-6203.4%↑92%-80781.0%
    ROE-95.8%↓111%842.9%↑2045%-43.3%↓112%369.4%↑708%45.7%
    Total Debt$352.8K↓91%$3.9M↑8%$3.6M↓46%$6.6M↑128%$2.9M
    Shareholders' Equity$4.3M↑212%-$3.8M↓114%$26.9M↑1322%-$2.2M↑56%-$5.0M
    Current Ratio1.39↑683%0.18↓57%0.41↓15%0.48↑930%0.05
    Debt / Equity0.08↑108%-1.01↓861%0.13↑104%-2.99↓422%-0.57
    Operating Cash Flow-$4.0M↓165%-$1.5M↑87%-$11.5M↓75%-$6.6M--
    Free Cash Flow-$6.1M↓305%-$1.5M↑87%-$11.8M↓65%-$7.1M--

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    AKAN vs Peers — Financial Grading

    Revenue$836664.00Bottom 25%
    Net Income$4.1MMedian
    ROE-95.8%Bottom 25%
    D/E0.08Top 25%
    Op. Margin-523.8%Bottom 25%
    Curr. Ratio1.39Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11